VIBRA-TABS (doxycycline hyclate) by Pfizer is tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. Approved for gonorrhea, chlamydia, syphilis and 3 more indications. First approved in 1980.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
VIBRA-TABS (doxycycline hyclate) is an oral tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, delivering bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. It is indicated for sexually transmitted infections (gonorrhea, chlamydia, syphilis), acne vulgaris, and Helicobacter pylori infection. The drug is nearly completely absorbed orally with a serum half-life of 18–22 hours, independent of renal function.
As a mature, off-patent tetracycline approaching loss of exclusivity, VIBRA-TABS commercial teams are likely focused on brand defense and niche positioning rather than growth expansion.
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral…
Worked on VIBRA-TABS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VIBRA-TABS offers stability in a mature, proven market but limited growth upside; roles are primarily commercial-focused on defensive market share, physician relationships, and patient access rather than launch or innovation. Career advancement on this product typically leads to portfolio expansion or transition to growth-stage brands within the organization.